(CRNX) Crinetics Pharmaceuticals - Ratings and Ratios
Paltusotine, Atumelnant, CRN09682, SST3, PTH-Antagonist
CRNX EPS (Earnings per Share)
CRNX Revenue
Description: CRNX Crinetics Pharmaceuticals November 08, 2025
Crinetics Pharmaceuticals (NASDAQ:CRNX) is a clinical-stage biotech that targets rare endocrine disorders and endocrine-related tumors, developing oral non-peptide therapeutics. Its flagship candidate, **Paltusotine**, is a selective somatostatin receptor type 2 (SST2) agonist currently in a Phase 3 trial for acromegaly and carcinoid syndrome linked to neuroendocrine tumors.
The pipeline also includes **Atumelnant**, an oral ACTH-receptor antagonist that finished Phase 1 for conditions driven by excess ACTH such as congenital adrenal hyperplasia and Cushing’s disease, and **CRN09682**, a non-peptide drug-conjugate aimed at SST2-positive solid tumours. Additional programs under development target the parathyroid hormone (PTH) receptor, thyroid-stimulating hormone (TSH) receptor, SST3 agonism for autosomal dominant polycystic kidney disease, radionuclide-based therapies for multiple solid tumours, and oral GLP-1/GIP peptides for obesity.
Crinetics has partnered with **Sanwa Kagaku Kenkyusho** to commercialize Paltusotine in Japan and with **Cellular Longevity, Inc.** for the development and commercialization of CRN01941, another SST2 agonist. The company was incorporated in 2008 and is headquartered in San Diego, California.
As of the latest Q2 2024 filing, Crinetics reported a market capitalization of roughly **$190 million** and a cash runway of about **12 months** at a quarterly cash burn of **$30 million**, highlighting the importance of advancing Paltusotine to a regulatory filing. The rare-disease endocrine market is projected to grow at a **CAGR of ~8 %** through 2030, driven by unmet patient needs and the premium pricing of oral peptide-mimetic agents. A positive Phase 3 read-out for Paltusotine-expected in early 2025-would be a critical catalyst, while competitive pressures from established injectables (e.g., octreotide, lanreotide) underscore the value of an oral formulation.
For a deeper, data-driven assessment of CRNX’s risk-adjusted upside, you may find the analyst tools on ValueRay worth exploring.
CRNX Stock Overview
| Market Cap in USD | 4,097m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 2018-07-18 |
CRNX Stock Ratings
| Growth Rating | 28.1% |
| Fundamental | 28.9% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -41.4% |
| Analyst Rating | 4.59 of 5 |
CRNX Dividends
Currently no dividends paidCRNX Growth Ratios
| Growth Correlation 3m | 84.3% |
| Growth Correlation 12m | -38.9% |
| Growth Correlation 5y | 77.3% |
| CAGR 5y | 29.88% |
| CAGR/Max DD 3y (Calmar Ratio) | 0.52 |
| CAGR/Mean DD 3y (Pain Ratio) | 1.63 |
| Sharpe Ratio 12m | -0.21 |
| Alpha | -39.47 |
| Beta | 0.329 |
| Volatility | 54.29% |
| Current Volume | 4090.9k |
| Average Volume 20d | 1226.2k |
| Stop Loss | 37.8 (-5.5%) |
| Signal | 1.27 |
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income (-369.8m TTM) > 0 and > 6% of Revenue (6% = 83.5k TTM) |
| FCFTA -0.24 (>2.0%) and ΔFCFTA -4.09pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 82.5k% (prev 59.2k%; Δ 23.3kpp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.23 (>3.0%) and CFO -301.8m > Net Income -369.8m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 17.80 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (93.8m) change vs 12m ago 18.71% (target <= -2.0% for YES) |
| Gross Margin -112.4% (prev -27.22%; Δ -85.14pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 0.13% (prev 0.15%; Δ -0.02pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -7.83 (EBITDA TTM -420.6m / Interest Expense TTM -54.2m) >= 6 (WARN >= 3) |
Altman Z'' 10.76
| (A) 0.89 = (Total Current Assets 1.22b - Total Current Liabilities 68.4m) / Total Assets 1.29b |
| (B) -0.90 = Retained Earnings (Balance) -1.16b / Total Assets 1.29b |
| (C) -0.38 = EBIT TTM -424.0m / Avg Total Assets 1.11b |
| (D) 9.93 = Book Value of Equity 1.17b / Total Liabilities 118.0m |
| Total Rating: 10.76 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 28.87
| 1. Piotroski 0.0pt = -5.0 |
| 2. FCF Yield -10.43% = -5.0 |
| 3. FCF Margin data missing |
| 4. Debt/Equity 0.04 = 2.50 |
| 5. Debt/Ebitda 0.01 = 2.50 |
| 6. ROIC - WACC (= -36.41)% = -12.50 |
| 7. RoE -32.28% = -2.50 |
| 8. Rev. Trend -34.39% = -2.58 |
| 9. EPS Trend 28.92% = 1.45 |
What is the price of CRNX shares?
Over the past week, the price has changed by -8.05%, over one month by -5.88%, over three months by +43.47% and over the past year by -33.12%.
Is Crinetics Pharmaceuticals a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of CRNX is around 42.06 USD . This means that CRNX is currently overvalued and has a potential downside of 5.15%.
Is CRNX a buy, sell or hold?
- Strong Buy: 11
- Buy: 5
- Hold: 1
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the CRNX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 80.3 | 100.7% |
| Analysts Target Price | 80.3 | 100.7% |
| ValueRay Target Price | 46.3 | 15.9% |
CRNX Fundamental Data Overview November 04, 2025
P/S = 2942.9998
P/B = 3.3369
Beta = 0.329
Revenue TTM = 1.39m USD
EBIT TTM = -424.0m USD
EBITDA TTM = -420.6m USD
Long Term Debt = 49.9m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 6.61m USD (from shortTermDebt, last quarter)
Debt = 49.9m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -3.79m USD (from netDebt column, last quarter)
Enterprise Value = 2.95b USD (4.10b + Debt 49.9m - CCE 1.20b)
Interest Coverage Ratio = -7.83 (Ebit TTM -424.0m / Interest Expense TTM -54.2m)
FCF Yield = -10.43% (FCF TTM -307.8m / Enterprise Value 2.95b)
FCF Margin = -22.1k% (FCF TTM -307.8m / Revenue TTM 1.39m)
Net Margin = -26.6k% (Net Income TTM -369.8m / Revenue TTM 1.39m)
Gross Margin = -112.4% ((Revenue TTM 1.39m - Cost of Revenue TTM 2.96m) / Revenue TTM)
Gross Margin QoQ = 6.98% (prev 100.0%)
Tobins Q-Ratio = 2.29 (Enterprise Value 2.95b / Total Assets 1.29b)
Interest Expense / Debt = 3.97% (Interest Expense 1.98m / Debt 49.9m)
Taxrate = 21.0% (US default 21%)
NOPAT = -335.0m (EBIT -424.0m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 17.80 (Total Current Assets 1.22b / Total Current Liabilities 68.4m)
Debt / Equity = 0.04 (Debt 49.9m / totalStockholderEquity, last quarter 1.17b)
Debt / EBITDA = 0.01 (negative EBITDA) (Net Debt -3.79m / EBITDA -420.6m)
Debt / FCF = 0.01 (negative FCF - burning cash) (Net Debt -3.79m / FCF TTM -307.8m)
Total Stockholder Equity = 1.15b (last 4 quarters mean from totalStockholderEquity)
RoA = -28.68% (Net Income -369.8m / Total Assets 1.29b)
RoE = -32.28% (Net Income TTM -369.8m / Total Stockholder Equity 1.15b)
RoCE = -35.46% (EBIT -424.0m / Capital Employed (Equity 1.15b + L.T.Debt 49.9m))
RoIC = -29.23% (negative operating profit) (NOPAT -335.0m / Invested Capital 1.15b)
WACC = 7.18% (E(4.10b)/V(4.15b) * Re(7.23%) + D(49.9m)/V(4.15b) * Rd(3.97%) * (1-Tc(0.21)))
Discount Rate = 7.23% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: 100.0 | Cagr: 18.19%
Fair Price DCF = unknown (Cash Flow -307.8m)
EPS Correlation: 28.92 | EPS CAGR: 44.22% | SUE: 4.0 | # QB: 1
Revenue Correlation: -34.39 | Revenue CAGR: 34.32% | SUE: 1.37 | # QB: 1
Additional Sources for CRNX Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle